Innovative approaches to the diagnosis, treatment and prevention of cancer have been the cornerstone of biopharma alliances for decades. While efforts to combat the COVID-19 pandemic have eclipsed all other activity in recent months, there has been sustained interest by investors and partners in novel targets, technologies and compounds in this therapeutic area. For example, at the time this article was written, three oncology companies had recently completed IPOs (Forma Therapeutics, Fusion Pharmaceuticals & Repare Therapeutics) and several more IPO-hopefuls are currently in registration (Greenwich, Poseida, Nkarta, Relay and iTeos).